XenoSTART

XenoSTART is an industry-leading contract research organization specializing in translational oncology. They offer the world’s largest collection of patient-derived xenograft (PDX) models—over 2,800—sourced from diverse global populations. These clinically annotated models enable pharmaceutical and biotech partners to accelerate discovery and de-risk early-stage cancer drug development by providing highly relevant efficacy data that mirrors contemporary patient populations. Their close integration with The START Center’s clinical trial network ensures access to up-to-date tumor samples, treatment histories, molecular data, and expert guidance throughout the clinic-to-bench pipeline[2][3][4][5].